Drug Profile
Dazodalibep - Horizon Therapeutics
Alternative Names: HZN-4920; HZN-4920 - Horizon Therapeutics; MEDI-4920; UNII-HN5US76BWF; VIB 4920; WHO 11399Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator MedImmune
- Developer Horizon Therapeutics plc; Viela Bio
- Class Antirheumatics; Biological proteins; Recombinant fusion proteins; Urologics
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Rheumatoid arthritis; Sjogren's syndrome
- Phase II Focal segmental glomerulosclerosis; Lupus nephritis; Renal transplant rejection
Most Recent Events
- 07 Feb 2024 Horizon Pharma Ireland plans a phase III trial for Sjögren's syndrome in unknown location (IV, Infusion) (NCT06245408)
- 10 Nov 2023 Efficacy and adverse events data from a phase II trial in Sjogren's syndrome presented at the ACR Convergence 2023 (ACR-2023)
- 10 Nov 2023 Pharmacodynamics data from a phase II trial in Sjogren's syndrome presented at the ACR Convergence 2023 (ACR-2023)